Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216181 | 0.87 | CNR2 (0.54) | CNR2CNR1TP53TDP1L3MBTL1 | |
| SCHEMBL2736539 | 0.84 | MAPT (0.40) | CNR2TP53TDP1PDE4BKDM4E | |
| SCHEMBL2736491 | 0.76 | TDP1 (0.44) | CNR2TP53TDP1L3MBTL1PDE4B | |
| SCHEMBL216494 | 0.76 | CNR2 (0.52) | CNR2CNR1TDP1L3MBTL1KDM4E | |
| SCHEMBL217634 | 0.76 | CNR2 (0.49) | CNR2CNR1TDP1L3MBTL1PDE4B | |
| SCHEMBL216146 | 0.76 | CNR2 (0.49) | CNR2CNR1TDP1L3MBTL1PDE4B | |
| SCHEMBL215196 | 0.72 | CNR2 (0.46) | CNR2CNR1TDP1L3MBTL1PDE4B | |
| SCHEMBL2760206 | 0.72 | L3MBTL1 (0.48) | CNR2CNR1TDP1L3MBTL1KDM4E | |
| SCHEMBL215944 | 0.72 | CNR2 (0.63) | CNR2CNR1TDP1L3MBTL1KDM4E | |
| SCHEMBL12434156 | 0.71 | ESR1 (0.49) | TDP1L3MBTL1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | CNR2 1/4885CNR1 2/4885TP53 4820/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885CNR1 1/4885TP53 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.